Design, Synthesis, and Characterization of Novel Tetrahydropyran-Based Bacterial Topoisomerase Inhibitors with Potent Anti-Gram-Positive Activity
- 11 September 2013
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 56 (18) , 7396-7415
Abstract
There is an urgent need for new antibacterial drugs that are effective against infections caused by multidrug-resistant pathogens. Novel nonfluoroquinolone inhibitors of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) have the potential to become such drugs because they display potent antibacterial activity and exhibit no target-mediated cross-resistance with fluoroquinolones. Bacterial topoisomerase inhibitors that are built on a tetrahydropyran ring linked to a bicyclic aromatic moiety through a syn-diol linker show potent anti-Gram-positive activity, covering isolates with clinically relevant resistance phenotypes. For instance, analog 49c was found to be a dual DNA gyrase–topoisomerase IV inhibitor, with broad antibacterial activity and low propensity for spontaneous resistance development, but suffered from high hERG K+ channel block. On the other hand, analog 49e displayed lower hERG K+ channel block while retaining potent in vitro antibacterial activity and acceptable frequency for resistance development. Furthermore, analog 49e showed moderate clearance in rat and promising in vivo efficacy against Staphylococcus aureus in a murine infection model.Keywords
This publication has 42 references indexed in Scilit:
- Multitarget ligands in antibacterial research: progress and opportunitiesExpert Opinion on Drug Discovery, 2012
- Challenges of Antibacterial DiscoveryClinical Microbiology Reviews, 2011
- Clinical and Economic Outcomes Attributable to Health Care–Associated Sepsis and PneumoniaArchives of internal medicine (1960), 2010
- Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2009
- Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens: No ESKAPEThe Journal of Infectious Diseases, 2008
- Estimating Health Care-Associated Infections and Deaths in U.S. Hospitals, 2002Public Health Reports®, 2007
- Drugs for bad bugs: confronting the challenges of antibacterial discoveryNature Reviews Drug Discovery, 2006
- Mechanisms of Resistance to QuinolonesClinical Infectious Diseases, 2005
- Bacterial Topoisomerase Inhibitors: Quinolone and Pyridone Antibacterial AgentsChemical Reviews, 2005
- Mechanism of quinolone resistance in Staphylococcus aureusJournal of Infection and Chemotherapy, 2000